GBS Inc. Reports Fourth Quarter and Full Year ended June 30, 2022 Preliminary Financial Results and Recent Business Highlights
Retrieved on:
Wednesday, August 31, 2022
Patient, COVID-19, University, Ecolab, Government, Sydney Medical School, Doctor of Philosophy, Exercise, Intelligence, R, GBS, Interim, Pacific Northwest Diabetes Research Institute, Board, Blood, IPO, Audit committee, University of Sydney, MPMC, Organization, Comparison, NEW, Financial compensation, GLOBE, Â, Fluorescent glucose biosensor, IFP, Nasdaq, Company, Saliva, Commercialization, Committee, ET, Webcast, Director, Acquisition, Chemical engineer, Clinical, Trial of the century, Development, Professional Football Compensation Committee, Income, Medical device, Video game, Management, Sand, Medical imaging, Research, Operation
NEW YORK, Aug. 31, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time monitoring and diagnostic testing for patients and their primary health practitioners at point of care, today announced its preliminary financial results for the fourth financial quarter and full-year ended June 30, 2022 and provided a business update. Management will host a webcast and conference call at 4:30 p.m. ET today.
Key Points:
- ET -
NEW YORK, Aug. 31, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time monitoring and diagnostic testing for patients and their primary health practitioners at point of care, today announced its preliminary financial results for the fourth financial quarter and full-year ended June 30, 2022 and provided a business update. - We continue our thorough due diligence process and remain on track to update the market in the near term.
- GBS is now proceeding with the next phase of the glucose biosensor development program, including two key parallel clinical studies.
- Employee Benefits Expense for the full fiscal year 2022 of $2.3 million compared to the year prior of $1.9 million.